. Author manuscript; available in PMC: 2008 Dec 1.

Published in final edited form as: J Med Chem. 2007 Jul 21;50(17):3973–3975. doi: 10.1021/jm070638m

Table 1.

MICs of 1a, 2a, and Representative Antibacterial Agents (Clinically Used) for Gram-Positive Bacteria Including Mycobacterium spp

		MIC (μg/mL)^a
entry	species and strain	1a^b	2a^c	RFP^d	INH^d	VCM^d	LZD^d
1	M. tuberculosis H37Rv	1.5	12.5	0.2	0.1
2	M. tuberculosis H37Rv INHr	1.5		0.2	>25
3	M. tuberculosis H37Rv RFPr	1.5		>25	0.05
4	M. bovis BCG Tokyo	3.1		0.1	0.1
5	M. avium Flamingo	6.3		3.1	>25
6	M. intracellulare ATCC15984	6.3		3.1	12.5
7	M. aurum	6.3		0.78	6.3
8	M. fortuitum NIHJ1615	12.5		>25	6.3
9	M. smegmatis Takeo	12.5		>25	12.5
10	MRSA high-resistance		4			1	2
11	VRSA 70		4			0.5	2
12	MRSA 92-1191		4			1	2
13	MRSA Mu50		8			1	2
14	MRSA LDZ-resistance06		8			1	32
15	S. aureus macrolide-resistance		4			1	2
16	E. faecalis NCTC12201 (VanA)		8			>128	2
17	E. faecalis NCTC12203 (VanA)		2			>128	4
18	S. aureus FDA209P		4			1	2
19	S. aureus Smith		8			1	2
20	E. coli NIHJ JC-2		>128			>128	128
21	K. pneumoniae NCTN9632		>128			>128	>128
22	P. mirabilis IFO3849		>128			>128	128
23	P. aeruginosa 46001		>128			>128	>128

The agar plate dilution method was used (see Supporting Information).

MICs against Gram-positive bacteria were >12.5.

MICs of 2a against Mycobacterium spp. were >10-fold higher than those of 1a.

VCM: vancomycin. LZD: linezolid. RFP: rifampicin. INH: isoniazid.